US Patent
US7718640 — Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Formulation · Assigned to Bayer Schering Pharma AG · Expires 2027-03-14 · 1y remaining
Vulnerability score
65/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects pharmaceutical compositions, specifically injectable formulations, that contain testosterone undecanoate in a vehicle with castor oil and a co-solvent.
USPTO Abstract
The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.
Drugs covered by this patent
- Aveed (TESTOSTERONE UNDECANOATE) · Marius
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.